On Oct. 9, the U.S. Senate passed the BIOSECURE Act as an amendment to the National Defense Authorization Act.
Our Take on the Latest from Washington
Chia-Feng Lu is a trusted advisor to investors, companies, and industry associations at the forefront of deep technology—where innovation intersects with complex regulatory regimes and national security considerations. He guides clients through the most challenging transactional and regulatory landscapes, helping them bring transformative technologies to market while safeguarding compliance and advancing strategic business goals.
Chia-Feng represents leading technology companies in high-stakes regulatory and legislative processes, working closely with policymakers to shape new laws, frameworks, and industry standards. His practice spans the development and commercialization of next-generation technologies, including advanced materials, artificial intelligence, biotechnology, quantum computing, robotics, semiconductors, and space. Over the past two decades, he has counseled on products grounded in Nobel Prize-winning science—one of which achieved blockbuster status in the pharmaceutical sector.
With a focus on cross-border corporate and regulatory law, Chia-Feng advises clients on mergers and acquisitions, strategic alliances, licensing, life-cycle management, and compliance strategies. His counsel is especially valued for addressing the rapidly evolving legal paradigms that govern deep technology across multiple jurisdictions.
Chia-Feng’s global perspective is central to his work. He regularly assists companies in navigating U.S. regulatory requirements while also providing insight into key markets across Europe, North Asia, and China. He counsels investment banks, private equity firms, and venture capital groups on regulatory developments, compliance challenges, and business risks in emerging technologies and sensitive supply chains.
Earlier in his career, Chia-Feng gained in-house experience with a U.S.-based global biotechnology company and a Japan-based global pharmaceutical leader, giving him a first-hand understanding of organizational priorities and the business realities facing technology-driven enterprises. Beyond his client work, he serves as an adjunct faculty member at leading academic institutions and holds advisory positions with several governments on policy development related to artificial intelligence, cell and gene therapy, robotics, semiconductors, shipbuilding, and the defense industry.
Through this combination of legal acumen, policy influence, and industry insight, Chia-Feng is widely recognized as a global strategic advisor for clients operating at the cutting edge of science, technology, and national security.
‡ Admitted in The District of Columbia and New York. Not admitted in Japan.
On Oct. 9, the U.S. Senate passed the BIOSECURE Act as an amendment to the National Defense Authorization Act.…